文献速递神经肌肉病

肌萎缩侧索硬化中的CHCHD10变异:证据在哪里?

CHCHD10 variants in amyotrophic lateral sclerosis: Where is the evidence?
PubMed 文献 · Ann Neurol · 2018-01-01

研究分析7个国家4365例全基因组测序的肌萎缩侧索硬化(ALS)患者和1832名对照的CHCHD10非同义单核苷酸变异,发现罕见编码突变负荷在ALS患者与对照间无增加(SKAT p=0.86,SKAT-O p=0.86,Firth p=0.88),提示CHCHD10突变并非单纯ALS的常见病因,不推荐在单纯ALS中常规检测CHCHD10突变。

要点

  • ALS患者与对照的罕见CHCHD10编码突变负荷无增加(SKAT p=0.86,SKAT-O p=0.86,Firth p=0.88)。
  • 少数携带潜在致病CHCHD10突变的患者表现为缓慢进展的ALS样表型,伴肌病和耳聋等非典型特征。
  • 作者认为,多数既往报道的CHCHD10变异在单纯ALS中的致病性证据不足,不推荐在单纯ALS中常规检测。

核心结论

  • CHCHD10突变作为单纯ALS的病因似乎远不如先前所提示的那样常见,而是与更复杂的表型相关。
  • 多数既往报道的变异在单纯ALS中的致病性似乎证据不足。
  • 本研究显示,不推荐在单纯ALS中常规检测CHCHD10突变。

研究设计与样本

  • 分析来自7个不同国家的4365例全基因组测序ALS患者和1832名对照。
  • 检测CHCHD10中所有非同义单核苷酸变异,并分别及合并进行遗传负荷检验(包括SKAT、SKAT-O和Firth逻辑回归)。

主要发现

  • 在病例中鉴定出3个新变异,但仅1个为ALS特异性;另鉴定出1个对照特异性突变。
  • ALS患者与对照相比,罕见编码突变负荷无增加(SKAT p=0.86,SKAT-O p=0.86,Firth p=0.88)。
  • 少数携带潜在致病CHCHD10突变的患者表现为缓慢进展的ALS样表型,伴肌病和耳聋等非典型特征。

临床怎么用

  • 作者认为,不推荐在单纯ALS中常规检测CHCHD10突变。
  • 作者指出,在确立遗传变异致病性时,充分的遗传学和功能学证据很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: After the initial report of a CHCHD10 mutation in mitochondrial disease with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations have been considered to be a frequent cause for ALS. However, the exact pathogenicity and clinical significance of these mutations remain unclear. Here, we aimed to determine the role of CHCHD10 mutations in ALS. METHODS: We analyzed 4,365 whole genome sequenced ALS patients and 1,832 controls from 7 different countries and examined all nonsynonymous single nucleotide variants in CHCHD10. These were tested for association with ALS, independently and in aggregate using several genetic burden tests (including sequence kernel association test [SKAT], optimal unified test [SKAT-O], and Firth logistic regression). RESULTS: We identified 3 new variants in cases, but only 1 was ALS-specific. Also, 1 control-specific mutation was identified. There was no increased burden of rare coding mutations among ALS patients compared to controls (p = 0.86, p = 0.86, and p = 0.88 for SKAT, SKAT-O, and Firth, respectively). The few carriers with potential pathogenic CHCHD10 mutations exhibited a slowly progressive ALS-like phenotype with atypical features such as myopathy and deafness. INTERPRETATION: CHCHD10 mutations seem to be a far less prevalent cause of pure ALS than previously suggested, and instead appear related to more complex phenotypes. There appears to be insufficient evidence for the pathogenicity of most previously reported variants in pure ALS. This study shows that routine testing for CHCHD10 mutations in pure ALS is not recommended and illustrates the importance of sufficient genetic and functional evidence in establishing pathogenicity of genetic variants. Ann Neurol 2018;83:110-116.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. CHCHD10 variants in amyotrophic lateral sclerosis: Where is the evidence? Ann Neurol. 2018. PMID: 30014597. doi:10.1002/ana.25273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。